-
公开(公告)号：US20170152321A1
公开(公告)日：2017-06-01
申请号：US15342668
申请日：2016-11-03
Applicant: Stemline Therapeutics, Inc.
Inventor： Ivan Bergstein
CPC classification number: C07K16/2866 , A61K39/00 , C07K16/18 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/55 , C12N5/163 , C12N9/1048 , C12N9/1077 , C12N15/86 , C12Y204/02036
Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.
-
公开(公告)号：US20170137513A1
公开(公告)日：2017-05-18
申请号：US15187579
申请日：2016-06-20
Applicant: Daniel A. Vallera , Jeff Lion
Inventor： Daniel A. Vallera , Jeff Lion
CPC classification number: C07K16/2803 , A61K38/00 , A61K38/164 , A61K38/19 , A61K47/6827 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K14/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/55 , C12N9/1077 , C12Y204/02036
Abstract: Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents or diagnostic agents for delivery to B cells.
-
公开(公告)号：US20170037386A1
公开(公告)日：2017-02-09
申请号：US15234297
申请日：2016-08-11
Applicant: Intrexon Corporation
Inventor： Timothy David Jones , Francis Joseph Carr
IPC: C12N9/10
CPC classification number: C12N9/1077 , A61K38/00 , A61K39/00 , A61K39/02 , C07K14/21 , C07K16/2803 , C07K2317/622 , C12Y204/02036
Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.
Abstract translation: 假单胞菌外毒素A或“PE”是由铜绿假单胞菌分泌的66kD，高效的细胞毒性蛋白质。 已经将各种形式的PE偶联到其它蛋白质，例如抗体，以产生选择性靶向所需表型细胞（例如肿瘤细胞）的治疗上有用的细胞毒素缀合物。 在本发明中，分析跨越约38kD形式的假单胞菌外毒素A蛋白的序列的免疫原性CD4 + T细胞表位的存在。 鉴定了6种免疫原性T细胞表位。 在每个表位内鉴定出残基，用于引入靶向氨基酸取代，以减少或预防可能施用于异源宿主的PE分子中的免疫原性T细胞应答。
-
公开(公告)号：US09562251B2
公开(公告)日：2017-02-07
申请号：US13701406
申请日：2011-06-02
Applicant: Ganesh M. Kishore , Jorgen Hansen , Jens Houghton-Larsen , Esben Halkjær Hansen , Michael Dalgaard Mikkelsen , Sabina Tavares , Charlotte Blom
Inventor： Ganesh M. Kishore , Jorgen Hansen , Jens Houghton-Larsen , Esben Halkjær Hansen , Michael Dalgaard Mikkelsen , Sabina Tavares , Charlotte Blom
CPC classification number: C12P19/56 , A23L27/36 , C12N9/1051 , C12N9/1077 , C12N15/52 , C12N15/8243 , C12N15/8245 , C12P7/42 , C12P15/00 , C12Y204/01126 , Y02P20/52
Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express novel recombinant genes encoding steviol biosynthetic enzymes and UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce steviol or steviol glycosides, e.g., rubusoside or Rebaudioside A, which can be used as natural sweeteners in food products and dietary supplements.
Abstract translation: 公开了重组微生物，植物和植物细胞，其被工程化以表达编码甜菊醇生物合成酶和UDP-糖基转移酶（UGT）的新型重组基因。 这样的微生物，植物或植物细胞可以产生甜菊醇或甜菊糖苷，例如可以在食品和膳食补充剂中用作天然甜味剂的罗红糖苷或雷鲍迪苷A.
-
公开(公告)号：US09534230B2
公开(公告)日：2017-01-03
申请号：US14456488
申请日：2014-08-11
Applicant: Bayer CropScience N.V.
Inventor： Marc De Block , Michael Metzlaff , Véronique Gossele
CPC classification number: C12N15/8271 , C12N9/1077 , C12N9/1241 , C12N9/80 , C12N9/93 , C12N15/8273 , C12Y207/07018 , C12Y305/01019
Abstract: Stress tolerance in plants and plant cells is achieved by using nucleotide sequences encoding enzymes involved in the NAD salvage synthesis pathway and/or the NAD de novo synthesis pathway e.g. for overexpression in plants.
Abstract translation: 通过使用编码参与NAD补救合成途径和/或NAD从头合成途径的酶的核苷酸序列，实现植物和植物细胞的胁迫耐受性。 在植物中过表达。
-
Patent Agency Ranking
16.发明授权Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses 有权用作诱导抗原特异性T细胞应答的免疫原性增强子的融合蛋白公开(公告)号：US09481714B2
公开(公告)日：2016-11-01
申请号：US14095760
申请日：2013-12-03
Applicant: TheVax Genetics Vaccine Co., Ltd.
Inventor： Chia-Mao Wu , Hsiu-Kang Chang
IPC: A61K39/00 , C07K14/005 , A61K39/21 , A61K47/48 , A61K39/385 , C07K14/705 , A61K39/12 , A61K39/135 , A61K39/17 , C07K14/81 , C12N9/10 , C12N9/14 , C07K14/21
CPC classification number: C07K14/005 , A61K39/12 , A61K39/135 , A61K39/17 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/6031 , C07K14/21 , C07K14/70596 , C07K14/81 , C07K2319/02 , C07K2319/04 , C07K2319/095 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C12N9/1077 , C12N9/14 , C12N2710/20022 , C12N2710/20034 , C12N2730/10122 , C12N2730/10134 , C12N2750/10022 , C12N2750/10034 , C12N2760/18134 , C12N2770/24222 , C12N2770/24234 , C12N2770/24334 , C12N2770/32134 , C12Y204/02036 , C12Y306/05002 , Y02A50/386
Abstract: A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.
Abstract translation: 公开了用作增强抗原特异性T细胞应答的免疫原增强剂的融合蛋白。 融合蛋白包括：（a）抗原呈递细胞（APC）结合结构域或CD91受体结合结构域; （b）蛋白转导结构域; 和（c）病原体的抗原，其中APC结合结构域或CD91受体结合结构域位于融合蛋白的N末端，并且病原体的抗原位于 蛋白转导结构域。 蛋白转导结构域选自：（i）包含T细胞致敏信号转导肽，接头和易位肽的融合多肽; （ii）T细胞增感信号转导肽; 和（iii）长度为34-112个氨基酸残基的易位肽。
-
17.发明授权公开(公告)号：US09371386B2
公开(公告)日：2016-06-21
申请号：US13256812
申请日：2010-03-11
Applicant: Daniel A. Vallera , Jeff Lion
Inventor： Daniel A. Vallera , Jeff Lion
CPC classification number: C07K16/2803 , A61K38/00 , A61K38/164 , A61K38/19 , A61K47/6827 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K14/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/55 , C12N9/1077 , C12Y204/02036
Abstract: Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents or diagnostic agents for delivery to B cells.
Abstract translation: 提供了具有VL和VH链反向取向的遗传工程靶向缀合物的方法和组合。 例如，在某些方面描述了靶向包含抗CD22和抗CD19的VL和VH链的缀合物。 在另一方面，本发明提供了包含用于递送至B细胞的治疗剂或诊断剂的方法和靶向缀合物。
-
公开(公告)号：US09163222B2
公开(公告)日：2015-10-20
申请号：US13676928
申请日：2012-11-14
Applicant: Kineta Two, LLC
Inventor： Shawn P Iadonato , Charles L Magness , P Campion Fellin , Christina A Scherer , Tory Hagen , Amy Olson
CPC classification number: C12N9/1241 , C12N9/1077 , C12N9/88 , C12Q1/6883 , C12Q2600/156
Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.
-
19.发明授权Method for producing hydroxycarboxylic acid by enhancing synthesis of coenzyme 有权通过增强辅酶的合成生产羟基羧酸的方法公开(公告)号：US09133444B2
公开(公告)日：2015-09-15
申请号：US13618898
申请日：2012-09-14
Applicant: Takashi Morishige , Mitsufumi Wada , Hitoshi Takahashi , Daisuke Mochizuki , Junko Tokuda
Inventor： Takashi Morishige , Mitsufumi Wada , Hitoshi Takahashi , Daisuke Mochizuki , Junko Tokuda
CPC classification number: C12N9/1077 , C12P7/42 , C12Y204/02011
Abstract: Hydroxycarboxylic acids are produced by using a microorganism that is improved in ability to produce nicotinamide adenine dinucleotide by deleting, mutating or substituting nadR gene in the microorganism or introducing a gene encoding nicotinic acid phosphoribosyltransferase.
Abstract translation: 通过使用通过在微生物中缺失，突变或取代nadR基因或引入编码烟酸磷酸核糖转移酶的基因来提高生产烟酰胺腺嘌呤二核苷酸能力的微生物来产生羟基羧酸。
-
公开(公告)号：US20150197575A1
公开(公告)日：2015-07-16
申请号：US14604047
申请日：2015-01-23
Applicant: Viventia Bio Inc.
Inventor： Nicholas Ronald GLOVER , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Denis Georges Bosc , Francina C. Chahal
IPC: C07K16/28 , A61K39/395 , A61K45/06 , C07K16/30 , A61K47/48
CPC classification number: C07K16/2884 , A61K38/00 , A61K39/39558 , A61K45/06 , A61K47/6819 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K14/415 , C07K16/30 , C07K16/3015 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/77 , C07K2319/55 , C12N9/1077 , G01N33/574 , G01N2333/471 , G01N2333/70585
Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.
Abstract translation: 本发明提供了肿瘤特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供包含附着于毒素或标记物的肿瘤特异性抗体的肿瘤特异性抗体和免疫缀合物及其方法和用途。 本发明还涉及使用本发明的肿瘤特异性抗体的诊断方法和试剂盒。
-
-
-
-
-
-
-
-
-
Search Results
551
records
(took 0.047 seconds)
